Nicholas Piramal
Encyclopedia
Piramal Healthcare,PHL)dates back to 1988 when the company ranked 48th steadily consolidated its position to become a formidable force of the industry, rising to top 3 with a market share of 4. 2 %. Last year the company did its most valuable deal in the history of Indian pharma with the sale of Healthcare Solutions business to Abbott for $ 3.8 billion.
Since its inception, Piramal has differentiated itself among Indian pharmaceutical companies by consistently respecting global intellectual property rights and partnering innovator pharmaceutical companies. The Company has products, technology and manufacturing partnerships with leading global innovator pharmaceutical companies. With assets across North America, Europe and Asia, Piramal Healthcare is also one of the largest custom manufacturing companies across the World.
It has significant presence in the global critical space with sales of anaesthesia products to over 100 countries.
The Company’s business model consists of two areas:
I – Pharma Business
1. Pharma Solutions (Custom Manufacturing for innovator companies)
2. Piramal Critical Care (Inhalation anaesthesia gases business)
3. Over the Counter (OTC)
4. Innovative discovery & commercialization
II – Financial Services Business
Piramal Healthcare is the flagship company of above US$ 1 billion Piramal Enterprises (PEL), one of India's largest diversified business houses. The group is headed by Mr. Ajay Piramal, who is also the Chairman of Piramal Group and among the most respected names in the Indian industry.
Line of Businesses –
I – Pharma Business
Pharma Solutions –
This is a global business that partners with MNC pharmaceutical companies to service their manufacturing and development needs. PHL has six facilities in India, two in UK and one in Canada. This division had sales of Rs. 10.2 billion in FY11.
Piramal Critical Care -
This is a global business that caters to drug requirement of hospitals worldwide. PHL has presence in 100+ countries globally either through distributors or through own office. PHL has one facility in India and one in US. This division had sales of Rs. 3.9 billion in FY11.
Consumer Products Division (OTC) -
This is a domestic business that caters to Indian consumers through sales of OTC products. We have a strong product portfolio such as Lacto Calamine – skin care range, Saridon – analgesic, Polycrol– digestive, Supractive Complete – a nutritional supplement, i-Pill – emergency contraceptive pill and Itchmasol – anti itching cream.
Innovative discovery & commercialization –
The Board of PHL has approved the scheme of De-merger of the New Chemical Entity (NCE) Research Unit of Piramal Life Sciences Limited (PLSL) into Piramal Healthcare Limited. Under the proposed De-merger scheme, each shareholder of PLSL will be entitled to one fully paid up equity share of Rs. 2 each of PHL for every four equity shares of Rs. 10 each held in PLSL. Since April 2007, when PLSL was de-merged from PHL as an independent discovery research company, it has made significant progress. The pipeline of R&D programs has increased from nine to twenty four with nine additional programs moving into Phase I/II clinical trials and two additional program moving into Phase II clinical trials. Subsequent to the significant progress that PLSL has made, the risk profile of NCE R&D activity has reduced considerably.
II - Financial Services Business
During FY2011, the Board of Directors has approved a plan for PHL to invest in subsidiaries engaged in financial services sector. To begin with, PHL will invest in NBFC engaged in lending to Infrastructure sector and to other sectors and will also invest in subsidiaries engaged in Fund Management for real estate & infrastructure sector.
Towards building a strong financial services business, the Board of PHL has approved acquisition of Indiareit Fund Advisors Pvt. Ltd. and Indiareit Investment Management Company for the total consideration of Rs. 2.3 billion. Indiareit Fund Advisors Pvt. Ltd. are advisors to the Indiareit Fund which is a domestic real estate Private Equity fund focused on the Indian markets. Indiareit Investment Management Company is manager to Offshore Real Estate Private Equity funds investing in India through the FDI route. The total fund size under management for these funds is Rs. 38 billion.
Joint Ventures
Allergan India Private Limited
Allergan India is the leader in the Indian ophthalmology space. It plays a pioneering role in developing the ophthalmology marketing the country through its marketing programs and services. Allergan’s major initiatives for the India market include improving awareness, diagnosis and treatment of glaucoma, developing the treatment of ocular surface disease/ dry eye, and introducing new surgical products, particularly in small incision cataract surgery, where it is market leader. The Company achieved a turnover of Rs. 1.4 billion in FY2011.
Since its inception, Piramal has differentiated itself among Indian pharmaceutical companies by consistently respecting global intellectual property rights and partnering innovator pharmaceutical companies. The Company has products, technology and manufacturing partnerships with leading global innovator pharmaceutical companies. With assets across North America, Europe and Asia, Piramal Healthcare is also one of the largest custom manufacturing companies across the World.
It has significant presence in the global critical space with sales of anaesthesia products to over 100 countries.
The Company’s business model consists of two areas:
I – Pharma Business
1. Pharma Solutions (Custom Manufacturing for innovator companies)
2. Piramal Critical Care (Inhalation anaesthesia gases business)
3. Over the Counter (OTC)
4. Innovative discovery & commercialization
II – Financial Services Business
Piramal Healthcare is the flagship company of above US$ 1 billion Piramal Enterprises (PEL), one of India's largest diversified business houses. The group is headed by Mr. Ajay Piramal, who is also the Chairman of Piramal Group and among the most respected names in the Indian industry.
Line of Businesses –
I – Pharma Business
Pharma Solutions –
This is a global business that partners with MNC pharmaceutical companies to service their manufacturing and development needs. PHL has six facilities in India, two in UK and one in Canada. This division had sales of Rs. 10.2 billion in FY11.
Piramal Critical Care -
This is a global business that caters to drug requirement of hospitals worldwide. PHL has presence in 100+ countries globally either through distributors or through own office. PHL has one facility in India and one in US. This division had sales of Rs. 3.9 billion in FY11.
Consumer Products Division (OTC) -
This is a domestic business that caters to Indian consumers through sales of OTC products. We have a strong product portfolio such as Lacto Calamine – skin care range, Saridon – analgesic, Polycrol– digestive, Supractive Complete – a nutritional supplement, i-Pill – emergency contraceptive pill and Itchmasol – anti itching cream.
Innovative discovery & commercialization –
The Board of PHL has approved the scheme of De-merger of the New Chemical Entity (NCE) Research Unit of Piramal Life Sciences Limited (PLSL) into Piramal Healthcare Limited. Under the proposed De-merger scheme, each shareholder of PLSL will be entitled to one fully paid up equity share of Rs. 2 each of PHL for every four equity shares of Rs. 10 each held in PLSL. Since April 2007, when PLSL was de-merged from PHL as an independent discovery research company, it has made significant progress. The pipeline of R&D programs has increased from nine to twenty four with nine additional programs moving into Phase I/II clinical trials and two additional program moving into Phase II clinical trials. Subsequent to the significant progress that PLSL has made, the risk profile of NCE R&D activity has reduced considerably.
II - Financial Services Business
During FY2011, the Board of Directors has approved a plan for PHL to invest in subsidiaries engaged in financial services sector. To begin with, PHL will invest in NBFC engaged in lending to Infrastructure sector and to other sectors and will also invest in subsidiaries engaged in Fund Management for real estate & infrastructure sector.
Towards building a strong financial services business, the Board of PHL has approved acquisition of Indiareit Fund Advisors Pvt. Ltd. and Indiareit Investment Management Company for the total consideration of Rs. 2.3 billion. Indiareit Fund Advisors Pvt. Ltd. are advisors to the Indiareit Fund which is a domestic real estate Private Equity fund focused on the Indian markets. Indiareit Investment Management Company is manager to Offshore Real Estate Private Equity funds investing in India through the FDI route. The total fund size under management for these funds is Rs. 38 billion.
Joint Ventures
Allergan India Private Limited
Allergan India is the leader in the Indian ophthalmology space. It plays a pioneering role in developing the ophthalmology marketing the country through its marketing programs and services. Allergan’s major initiatives for the India market include improving awareness, diagnosis and treatment of glaucoma, developing the treatment of ocular surface disease/ dry eye, and introducing new surgical products, particularly in small incision cataract surgery, where it is market leader. The Company achieved a turnover of Rs. 1.4 billion in FY2011.